数据安全监查委员会向非成员分享期中结果指标的相关因素探索
该研究基于2015年对临床试验学会和国际临床生物统计学会成员的在线调查,探索与数据安全监查委员会(DSMB)向非DSMB成员分享特定期中结果指标相关的人口学因素。主要发现:参与超过15项私营企业资助试验与不赞成分享期中对照事件率(IControlER)相关(OR=2.92;95%CI:1.31,6.52;p=0.012),且与分享自适应条件功效(ACP)的感知有用性增加2.35分正相关(beta=2.35;95%CI:0.45,4.05;p=0.017)。
要点
- 参与超过15项私营企业资助试验者更不赞成DSMB分享期中对照事件率。
- 同类人群认为分享自适应条件功效(ACP)更有用,评分增加2.35分。
- 结果为探索性,受高无应答和缺失数据限制,需谨慎解读。
核心结论
- 参与超过15项私营企业资助试验是与DSMB不分享期中对照事件率(IControlER)相关的人口学因素,并与分享ACP的感知有用性增加相关。
研究设计与样本
- 2015年对临床试验学会(SCT)和国际临床生物统计学会(ISCB)成员进行在线调查,邀请约3136人,应答率12%(371/3136)。
- 采用二元逻辑回归和多元线性回归分别探索人口学因素与分享特定期中结果指标及感知有用性的关联,并用多重插补(MI)进行敏感性分析。
主要发现
- 参与超过15项私营企业资助试验与不赞成分享IControlER相关(OR=2.92;95%CI:1.31,6.52;p=0.012)。
- 参与超过15项私营企业资助试验与分享ACP的感知有用性增加2.35分正相关(beta=2.35;95%CI:0.45,4.05;p=0.017)。
- 敏感性分析后结果相似。
临床怎么用
- DSMB在决定是否向非成员分享期中结果指标时,可考虑成员参与私营企业资助试验的经验背景。
- 对于参与大量私营企业资助试验的成员,需关注其对分享IControlER的保留态度及对分享ACP的积极感知。
局限性
- 应答率仅12%,存在高无应答和缺失数据,结果应视为探索性第一步,不能作为确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sharing interim result measures by the Data Safety Monitoring Board (DSMB) with non-DSMB members is an important issue that can affect trial integrity. Currently, it is unclear if there are demographic factors associated with sharing such information. This study's objective is to primarily explore the demographic factors associated with the DSMB sharing certain interim result measures and secondarily, explore demographic factors associated with the perceived usefulness in sharing certain interim result measures, with non-DSMB members. METHODS: We conducted an online survey of members of the Society of Clinical Trials (SCT) and International Society of Clinical Biostatistics (ISCB) in 2015 asking their professional views on the DSMB sharing interim trial results, specifically the interim control event rate (IControlER), interim combined even rate (ICombinedER), adaptive conditional power (ACP) and unconditional conditional power (UCP) with non-DSMB members. Binary logistic and multiple linear regressions were used to explore if demographic factors were associated with sharing a certain interim result measure and the perceived usefulness of sharing that interim result measure, respectively. Multiple imputation (MI) was used to evaluate the impact of missing data as a sensitivity analysis. RESULTS: Approximately 3136 (936 from SCT + ~ 2200 from ISCB) members were invited (response rate of 12%; [371/3136]. Two main findings: (1) involvement in more than 15 private industry-sponsored trials was associated with not endorsing the sharing of the IControlER (odds ratio [OR] = 2.92; 95% confidence interval [CI]: 1.31, 6.52]; p = 0.012), and (2) involvement in more than 15 private industry-sponsored trials was associated positively with an increase in the perceived usefulness in sharing the ACP by 2.35 points (beta coefficient estimate = 2.35 [95% CI: 0.45, 4.05], p = 0.017. The findings were similar after sensitivity analyses. CONCLUSIONS: An individual involved with more than 15 trials that had some form of private industry sponsorship is a demographic factor associated with NOT sharing the IControlER by the DSMB and an increased perceived usefulness in sharing the ACP at interim. Further studies are needed to evaluate for these demographic factors given the limitations of this study related to missing data. Due to some key limitations, regarding high non-response and missing data, we caution interpreting the results as definitive, but rather look at them as a first exploratory step to find potential associations for further evaluation.
引用
- Borg Debono V, Mbuagbaw L, Paul J, et al. Exploring factors associated with views on sharing of certain interim trial result measures by the data safety monitoring board (DSMB) with non-DSMB members. Trials. 2018. PMID: 30419939. doi:10.1186/s13063-018-2938-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。